JP7528212B2 - 神経保護のための方法および組成物 - Google Patents

神経保護のための方法および組成物 Download PDF

Info

Publication number
JP7528212B2
JP7528212B2 JP2022530807A JP2022530807A JP7528212B2 JP 7528212 B2 JP7528212 B2 JP 7528212B2 JP 2022530807 A JP2022530807 A JP 2022530807A JP 2022530807 A JP2022530807 A JP 2022530807A JP 7528212 B2 JP7528212 B2 JP 7528212B2
Authority
JP
Japan
Prior art keywords
disease
disorder
injury
antisense oligonucleotide
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022530807A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023503994A (ja
Inventor
レベンタール,リザ
エングバー,トーマス
エドゥアルド クラウス,ラウル
デブラジ,ラジェシュ
オーウェン ヒューズ,ロバート
ボサナック,トッド
アグラワル,スディール
エイ パッシーニ,マルコ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Disarm Therapeutics Inc
Original Assignee
Disarm Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Disarm Therapeutics Inc filed Critical Disarm Therapeutics Inc
Publication of JP2023503994A publication Critical patent/JP2023503994A/ja
Priority to JP2024075968A priority Critical patent/JP7796797B2/ja
Application granted granted Critical
Publication of JP7528212B2 publication Critical patent/JP7528212B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/02—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2)
    • C12Y302/02006—NAD(P)+ nucleosidase (3.2.2.6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/312—Phosphonates
    • C12N2310/3125—Methylphosphonates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/316—Phosphonothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
JP2022530807A 2019-11-26 2020-11-25 神経保護のための方法および組成物 Active JP7528212B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024075968A JP7796797B2 (ja) 2019-11-26 2024-05-08 神経保護のための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962940437P 2019-11-26 2019-11-26
US62/940,437 2019-11-26
PCT/US2020/062289 WO2021108602A1 (en) 2019-11-26 2020-11-25 Methods and compositions for neuroprotection

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024075968A Division JP7796797B2 (ja) 2019-11-26 2024-05-08 神経保護のための方法および組成物

Publications (2)

Publication Number Publication Date
JP2023503994A JP2023503994A (ja) 2023-02-01
JP7528212B2 true JP7528212B2 (ja) 2024-08-05

Family

ID=74046136

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022530807A Active JP7528212B2 (ja) 2019-11-26 2020-11-25 神経保護のための方法および組成物
JP2024075968A Active JP7796797B2 (ja) 2019-11-26 2024-05-08 神経保護のための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024075968A Active JP7796797B2 (ja) 2019-11-26 2024-05-08 神経保護のための方法および組成物

Country Status (11)

Country Link
US (1) US12595481B2 (cg-RX-API-DMAC7.html)
EP (1) EP4065714A1 (cg-RX-API-DMAC7.html)
JP (2) JP7528212B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220119366A (cg-RX-API-DMAC7.html)
CN (1) CN115176002A (cg-RX-API-DMAC7.html)
AU (1) AU2020391206A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022009772A2 (cg-RX-API-DMAC7.html)
IL (1) IL293123A (cg-RX-API-DMAC7.html)
MX (1) MX2022006146A (cg-RX-API-DMAC7.html)
TW (1) TW202134436A (cg-RX-API-DMAC7.html)
WO (1) WO2021108602A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024112834A (ja) * 2019-11-26 2024-08-21 ディスアーム セラピューティクス, インコーポレイテッド 神経保護のための方法および組成物

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CR20240380A (es) * 2022-03-14 2024-10-03 Lilly Co Eli Agentes de interferencia de arn de sarm1
CN116059367B (zh) * 2022-07-15 2025-02-18 浙江乘时佳生物科技有限公司 一种治疗阿尔茨海默症的sarm1抑制剂
IL318437A (en) * 2022-07-21 2025-03-01 Amylyx Pharmaceuticals Inc Compositions containing oligonucleotides, and methods of using them
TW202547525A (zh) 2024-02-02 2025-12-16 美商美國禮來大藥廠 SARM1 RNAi藥劑
GB202408068D0 (en) 2024-06-06 2024-07-24 Univ London Treatment of cancer of the central nervous system
WO2025261431A1 (zh) * 2024-06-19 2025-12-26 上海拓界生物医药科技有限公司 靶向SARM1的RNAi剂及其医药用途

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140079712A1 (en) 2011-06-24 2014-03-20 University Of Miami Therapeutic Applications Targeting SARM1
WO2017164230A1 (ja) 2016-03-23 2017-09-28 国立大学法人 岡山大学 リン酸化sarm1、抗体、sarm1リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、sarm1改変体及び使用
WO2018057989A1 (en) 2016-09-24 2018-03-29 Washington University INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF
WO2019079572A1 (en) 2017-10-18 2019-04-25 Washington University NEGATIVE DOMINANT SARM1 MOLECULES AS A THERAPEUTIC STRATEGY FOR NEURODEGENERATIVE DISEASES OR DISORDERS
WO2019236890A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
WO2019236879A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
WO2019236884A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040096830A1 (en) * 2002-11-16 2004-05-20 Isis Pharmaceuticals Inc. Modulation of protein kinase D2 expression
US7250496B2 (en) * 2002-11-14 2007-07-31 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory genes and uses thereof
US20050244851A1 (en) * 2004-01-13 2005-11-03 Affymetrix, Inc. Methods of analysis of alternative splicing in human
CA2566519C (en) * 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
US7901882B2 (en) * 2006-03-31 2011-03-08 Affymetrix, Inc. Analysis of methylation using nucleic acid arrays
JP2013003911A (ja) * 2011-06-17 2013-01-07 Sony Corp 電子機器、電子機器の制御方法およびプログラム
EP3294342A4 (en) 2015-05-08 2018-11-07 President and Fellows of Harvard College Universal donor stem cells and related methods
EP3481857B1 (en) 2016-07-06 2026-02-11 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of pain related disorders
WO2018154413A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of dystrophic epidermolysis bullosa (deb) and other collagen type vii alpha 1 chain (col7a1) gene related conditions or disorders
WO2021108602A1 (en) 2019-11-26 2021-06-03 Disarm Therapeutics, Inc. Methods and compositions for neuroprotection

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140079712A1 (en) 2011-06-24 2014-03-20 University Of Miami Therapeutic Applications Targeting SARM1
WO2017164230A1 (ja) 2016-03-23 2017-09-28 国立大学法人 岡山大学 リン酸化sarm1、抗体、sarm1リン酸化阻害剤、神経変性疾患の予防又は治療薬、スクリーニング方法、sarm1改変体及び使用
WO2018057989A1 (en) 2016-09-24 2018-03-29 Washington University INHIBITORS OF SARM1 NADase ACTIVITY AND USES THEREOF
WO2019079572A1 (en) 2017-10-18 2019-04-25 Washington University NEGATIVE DOMINANT SARM1 MOLECULES AS A THERAPEUTIC STRATEGY FOR NEURODEGENERATIVE DISEASES OR DISORDERS
WO2019236890A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
WO2019236879A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1
WO2019236884A1 (en) 2018-06-07 2019-12-12 Disarm Therapeutics, Inc. Inhibitors of sarm1

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024112834A (ja) * 2019-11-26 2024-08-21 ディスアーム セラピューティクス, インコーポレイテッド 神経保護のための方法および組成物
JP7796797B2 (ja) 2019-11-26 2026-01-09 ディスアーム セラピューティクス, インコーポレイテッド 神経保護のための方法および組成物

Also Published As

Publication number Publication date
JP2024112834A (ja) 2024-08-21
JP2023503994A (ja) 2023-02-01
WO2021108602A1 (en) 2021-06-03
EP4065714A1 (en) 2022-10-05
AU2020391206A1 (en) 2022-05-19
CN115176002A (zh) 2022-10-11
CA3159374A1 (en) 2021-06-03
MX2022006146A (es) 2022-10-18
IL293123A (en) 2022-07-01
US20230242909A1 (en) 2023-08-03
BR112022009772A2 (pt) 2022-08-16
KR20220119366A (ko) 2022-08-29
TW202134436A (zh) 2021-09-16
US12595481B2 (en) 2026-04-07
JP7796797B2 (ja) 2026-01-09

Similar Documents

Publication Publication Date Title
JP7796797B2 (ja) 神経保護のための方法および組成物
Picca et al. Mitophagy in human health, ageing and disease
CN113164508B (zh) 与神经保护剂组合的sarm1抑制剂
JP5710001B2 (ja) miRNAをターゲットとした神経変性疾患の治療
CN106146591B (zh) 血管生成素样3表达的调节
EP3394259B1 (en) Compositions and methods for decreasing tau expression
JP6492003B2 (ja) 発作を減少させるためおよび神経変性症候群を改質するためにタウ発現を調節する方法
US20230340477A1 (en) Uses for prevention or treatment of brain diseases using microrna
US20180264027A1 (en) Method for treating a degenerative neurological disorders comprising administering asm inhibitor
Wang et al. Tetrandrine alleviates cerebral ischemia/reperfusion injury by suppressing NLRP3 inflammasome activation via Sirt-1
TW201641691A (zh) Tau反義寡聚物及其用途
CN109072238A (zh) 使用靶向结缔组织生长因子的rna复合物治疗特发性肺纤维化
JP7463621B2 (ja) ミトコンドリアアミドキシム還元成分1(marc1)発現を阻害するための組成物および方法
US20190142860A1 (en) Nucleic acid based tia-1 inhibitors
JP2024504266A (ja) リジン分解関連障害の治療
US9434945B2 (en) Use of miR-23a-3p and/or miR-27a-3p mimics as therapeutic agents for inhibition of neuronal apoptosis following brain injury
US20200255839A1 (en) Method for treating a degenerative neurological disorders comprising administering asm inhibitor
CN117897483A (zh) 用于抑制α-1抗胰蛋白酶表达的组合物和方法
CA3159374C (en) Methods and compositions for neuroprotection
US20110218233A1 (en) Treatment of scleroderma
TW201238973A (en) MiRNAs in joint disease
TW201241179A (en) MiRNAs in joint disease
JP2022545987A (ja) eIF4E阻害剤を含むeIF4E活性増加に関わる状態の診断または治療用組成物
WO2025264967A1 (en) Agents and/or compositions useful for modulating cis-regulatory elements in synucleinopathies and methods for identifying agents and compositions thereof
CN119654413A (zh) Itfg1抑制性核酸

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220722

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220722

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230725

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231024

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240109

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240508

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240510

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240529

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240709

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240724

R150 Certificate of patent or registration of utility model

Ref document number: 7528212

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150